{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:57:14Z","timestamp":1794581834104,"version":"4.9.1"},"reference-count":101,"publisher":"Bentham Science Publishers Ltd.","issue":"16","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,12,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Bone is a dynamic tissue that continuously undergoes the modeling and remodeling\nprocess to maintain its strength and firmness. Bone remodeling is determined by the functioning\nof osteoblast and osteoclast cells. The imbalance between the functioning of osteoclast and osteoblast\ncells leads to osteoporosis. Osteoporosis is divided into primary and secondary osteoporosis.\nGenerally, osteoporosis is diagnosed by measuring bone mineral density (BMD) and various osteoblast\nand osteoclast cell markers.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> Relevant literature reports have been studied and data has been collected using various\nsearch engines like google scholar, scihub, sciencedirect, pubmed, etc. A thorough understanding of\nthe mechanism of bone targeting strategies has been discussed and related literature has been studied\nand compiled.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Bone remodeling process has been described in detail including various approaches for targeting\nbone. Several bone targeting moieties have been stated in detail along with their mechanisms.\nTargeting of osteoclasts and osteoblasts using various nanocarriers has been discussed in separate sections.\nThe toxicity issues or Biosafety related to the use of nanomaterials have been covered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The treatment of osteoporosis targets the inhibition of bone resorption and the use of\nagents that promote bone mineralization to slow disease progression. Current osteoporosis therapy involves\nthe use of targeting moieties such as bisphosphonates and tetracyclines for targeting various\ndrugs. Nanotechnology has been used for targeting various drug molecules such as RANKLinhibitors,\nparathyroid hormone analogues, estrogen agonists and antagonists, Wnt signaling enhancer\nand calcitonin specifically to bone tissue (osteoclast and osteoblasts). So, a multicomponent treatment\nstrategy targeting both the bone cells will be more effective rather than targeting only osteoclasts and\nit will be a potential area of research in bone targeting used to treat osteoporosis.\nThe first section of the review article covers various aspects of bone targeting. Another section comprises\ndetails of various targeting moieties such as bisphosphonates, tetracyclines; and various\nnanocarriers developed to target osteoclast and osteoblast cells and summarized data on in vivo models\nhas been used for assessment of bone targeting, drawbacks of current strategies and future perspectives.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200731173522","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T16:56:38Z","timestamp":1596214598000},"page":"1640-1651","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment"],"prefix":"10.2174","volume":"21","author":[{"given":"Malkiet","family":"Kaur","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Nagpal","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","volume":"64","author":"Low S.A.","year":"2012","unstructured":"Low S.A.; Kope\u010dek J.; Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 2012,64(12),1189-1204","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=2","year":"2004","unstructured":"Rockville. Bone health and Osteoporosis- A report of the surgeon\ngeneral, U.S.A. department of Health and Human services, Office\nof Surgeon general 2004"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2147\/IJWH.S54623","volume":"7","author":"Khadilkar A.V.","year":"2015","unstructured":"Khadilkar A.V.; Mandlik R.M.; Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health 2015,7,841-850","journal-title":"Int J Womens Health"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"Cummings S.R.","year":"2002","unstructured":"Cummings S.R.; Melton L.J.; Epidemiology and outcomes of osteoporotic fractures. Lancet 2002,359(9319),1761-1767","journal-title":"Lancet"},{"key":"ref=5","first-page":"11","volume":"5","author":"Masi L.","year":"2008","unstructured":"Masi L.; Epidemiology of osteoporosis. Clin Cases Miner Bone Metab 2008,5(1),11-13","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref=6","author":"Coe F.L.","year":"2002","unstructured":"Coe F.L.; Favus M.J.;  Disorders of bone and mineral metabolism 2002","journal-title":"Disorders of bone and mineral metabolism"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"Langdahl B.","year":"2016","unstructured":"Langdahl B.; Ferrari S.; Dempster D.W.; Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2016,8(6),225-235","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1359\/jbmr.090105","volume":"24","author":"Bilezikian J.P.","year":"2009","unstructured":"Bilezikian J.P.; Matsumoto T.; Bellido T.; Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 2009,24(3),373-385","journal-title":"J Bone Miner Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"Rodan G.A.","year":"2000","unstructured":"Rodan G.A.; Martin T.J.; Therapeutic approaches to bone diseases. Science 2000,289(5484),1508-1514","journal-title":"Science"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"S\u00f6zen T.","year":"2017","unstructured":"S\u00f6zen T.; \u00d6z\u0131\u015f\u0131k L.; Ba\u015faran N.\u00c7.; An overview and management of osteoporosis. Eur J Rheumatol 2017,4(1),46-56","journal-title":"Eur J Rheumatol"},{"key":"ref=11","unstructured":"Medscape. How does the WHO define osteoporosis?"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11914-016-0306-3","volume":"14","author":"Barry M.","year":"2016","unstructured":"Barry M.; Pearce H.; Cross L.; Tatullo M.; Gaharwar A.K.; Advances in Nanotechnology for the treatment of osteoporosis. Curr Osteoporos Rep 2016,14(3),87-94","journal-title":"Curr Osteoporos Rep"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1730978","volume":"\u2022","author":"Paspaliaris V.","year":"2019","unstructured":"Paspaliaris V.; Kolios G.; Stem cells in osteoporosis: from biology to new therapeutic approaches. Stem Cells Int 2019,\u2022","journal-title":"Stem Cells Int"},{"key":"ref=14","first-page":"92","volume":"43","author":"Tu K.N.","year":"2018","unstructured":"Tu K.N.; Lie J.D.; Wan C.K.V.; Osteoporosis: a review of treatment options. P 2018,43(2),92-104","journal-title":"P"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"Mazziotti G.","year":"2012","unstructured":"Mazziotti G.; Bilezikian J.; Canalis E.; Cocchi D.; Giustina A.; New understanding and treatments for osteoporosis. Endocrine 2012,41(1),58-69","journal-title":"Endocrine"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11914-017-0350-7","volume":"15","author":"Lewiecki E.M.","year":"2017","unstructured":"Lewiecki E.M.; Osteoporosis: Treat-to-Target. Curr Osteoporos Rep 2017,15(2),103-109","journal-title":"Curr Osteoporos Rep"},{"key":"ref=17","first-page":"43","volume":"19","author":"Dobbs M.B.","year":"1999","unstructured":"Dobbs M.B.; Buckwalter J.; Saltzman C.; Osteoporosis: the increasing role of the orthopaedist. Iowa Orthop J 1999,19,43-52","journal-title":"Iowa Orthop J"},{"key":"ref=18","unstructured":"Premier orthopaedics The different types of osteoporosis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.copbio.2016.02.029","volume":"40","author":"Newman M.R.","year":"2016","unstructured":"Newman M.R.; Benoit D.S.; Local and targeted drug delivery for bone regeneration. Curr Opin Biotechnol 2016,40,125-132","journal-title":"Curr Opin Biotechnol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"Cosman F.","year":"2014","unstructured":"Cosman F.; de Beur S.J.; LeBoff M.S.; National Osteoporosis Foundation. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014,25(10),2359-2381","journal-title":"Osteoporos Int"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.medengphy.2019.10.011","volume":"76","author":"Jean-Louis M.","year":"2020","unstructured":"Jean-Louis M.; Claudia C.Y.; Jean-Marie R.; Patrick C.; Simulating pharmaceutical treatment effects on osteoporosis via a bone remodeling algorithm targeting hypermineralized sites. Med Eng Phys 2020,76,56-68","journal-title":"Med Eng Phys"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrendo.2011.146","volume":"8","author":"Chen J.S.","year":"2011","unstructured":"Chen J.S.; Sambrook P.N.; Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 2011,8(2),81-91","journal-title":"Nat Rev Endocrinol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3934\/bioeng.2017.2.259","volume":"4","author":"Mora Raimundo P.","year":"2017","unstructured":"Mora Raimundo P.; Manzano Garc\u00eda M.; Vallet Reg\u00ed M.; Nanoparticles for the treatment of osteoporosis. AIMS Bioeng 2017,4(2),259-274","journal-title":"AIMS Bioeng"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1210\/jcem.86.3.7366","volume":"86","author":"Rosen C.J.","year":"2001","unstructured":"Rosen C.J.; Bilezikian J.P.; Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001,86(3),957-964","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=25","unstructured":"FDA news release FDA","journal-title":"FDA news release"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.drudis.2017.04.021","volume":"22","author":"Cheng H.","year":"2017","unstructured":"Cheng H.; Chawla A.; Yang Y.; Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today 2017,22(9),1336-1350","journal-title":"Drug Discov Today"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2147\/IJWH.S53489","volume":"6","author":"Modi A.","year":"2014","unstructured":"Modi A.; Sajjan S.; Gandhi S.; Challenges in implementing and maintaining osteoporosis therapy. Int J Womens Health 2014,6,759-769","journal-title":"Int J Womens Health"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"Khosla S.","year":"2017","unstructured":"Khosla S.; Hofbauer L.C.; Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 2017,5(11),898-907","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1568010054022015","volume":"4","author":"Tanaka Y.","year":"2005","unstructured":"Tanaka Y.; Nakayamada S.; Okada Y.; Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005,4(3),325-328","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.2147\/IJN.S44393","volume":"8","author":"Gu W.","year":"2013","unstructured":"Gu W.; Wu C.; Chen J.; Xiao Y.; Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Int J Nanomedicine 2013,8,2305-2317","journal-title":"Int J Nanomedicine"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/bmb\/ldw033","volume":"119","author":"Chan C.K.","year":"2016","unstructured":"Chan C.K.; Mason A.; Cooper C.; Dennison E.; Novel advances in the treatment of osteoporosis. Br Med Bull 2016,119(1),129-142","journal-title":"Br Med Bull"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.22203\/eCM.v031a23","volume":"31","author":"Alencastre I.S.","year":"2016","unstructured":"Alencastre I.S.; Sousa D.M.; Alves C.J.; Delivery of pharmaceutics to bone: Nanotechnologies, high-throughput processing and in silico mathematical models. Eur Cell Mater 2016,31,355-381","journal-title":"Eur Cell Mater"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/ijms18071345","volume":"18","author":"Stapleton M.","year":"2017","unstructured":"Stapleton M.; Sawamoto K.; Alm\u00e9ciga-D\u00edaz C.J.; Development of bone targeting drugs. Int J Mol Sci 2017,18(7),1345","journal-title":"Int J Mol Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/BOR.0b013e32832cbc2a","volume":"21","author":"Deal C.","year":"2009","unstructured":"Deal C.; Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 2009,21(4),380-385","journal-title":"Curr Opin Rheumatol"},{"key":"ref=35","unstructured":"International osteoporosis foundation Osteoporosis musculoskeletal\ndisorders"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1210\/jc.2004-2168","volume":"90","author":"Bonnelye E.","year":"2005","unstructured":"Bonnelye E.; Aubin J.E.; Estrogen receptor-related receptor \u03b1: a mediator of estrogen response in bone. J Clin Endocrinol Metab 2005,90(5),3115-3121","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/B978-012098652-1.50156-6","author":"Pilbeam C.C.","year":"2002","unstructured":"Pilbeam C.C.; Harrison J.R.; Raisz L.G.;  Prostaglandins and bone metabolism in principles of bone biology 2002,979-995","journal-title":"Prostaglandins and bone metabolism in principles of bone biology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-11-0132","volume":"165","author":"Marie P.J.","year":"2011","unstructured":"Marie P.J.; Kassem M.; Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol 2011,165(1),1-10","journal-title":"Eur J Endocrinol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Gong Y.","year":"2001","unstructured":"Gong Y.; Slee R.B.; Fukai N.; LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell Osteoporosis-Pseudoglioma Syndrome Collaborative Group2001,107(4),513-523","journal-title":"Cell"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"Bucay N.","year":"1998","unstructured":"Bucay N.; Sarosi I.; Dunstan C.R.; osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998,12(9),1260-1268","journal-title":"Genes Dev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1172\/JCI114459","volume":"85","author":"Carano A.","year":"1990","unstructured":"Carano A.; Teitelbaum S.L.; Konsek J.D.; Schlesinger P.H.; Blair H.C.; Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990,85(2),456-461","journal-title":"J Clin Invest"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"Drake M.T.","year":"2008","unstructured":"Drake M.T.; Clarke B.L.; Khosla S.; Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008,83(9),1032-1045","journal-title":"Mayo Clin Proc"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrendo.2013.154","volume":"9","author":"Canalis E.","year":"2013","unstructured":"Canalis E.; Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol 2013,9(10),575-583","journal-title":"Nat Rev Endocrinol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"Coxon F.P.","year":"2006","unstructured":"Coxon F.P.; Thompson K.; Rogers M.J.; Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006,6(3),307-312","journal-title":"Curr Opin Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","volume":"9","author":"Farrell K.B.","year":"2018","unstructured":"Farrell K.B.; Karpeisky A.; Thamm D.H.; Zinnen S.; Bisphosphonate conjugation for bone specific drug targeting. Bone Rep 2018,9,47-60","journal-title":"Bone Rep"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1021\/mp8002368","volume":"6","author":"Doschak M.R.","year":"2009","unstructured":"Doschak M.R.; Kucharski C.M.; Wright J.E.; Zernicke R.F.; Uluda\u011f H.; Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm 2009,6(2),634-640","journal-title":"Mol Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bmc.2009.12.041","volume":"18","author":"Morioka M.","year":"2010","unstructured":"Morioka M.; Kamizono A.; Takikawa H.; Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem 2010,18(3),1143-1148","journal-title":"Bioorg Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijpharm.2010.04.015","volume":"394","author":"Bhandari K.H.","year":"2010","unstructured":"Bhandari K.H.; Newa M.; Uludag H.; Doschak M.R.; Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin. Int J Pharm 2010,394(1-2),26-34","journal-title":"Int J Pharm"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s11095-013-1237-7","volume":"31","author":"Yang Y.","year":"2014","unstructured":"Yang Y.; Bhandari K.H.; Panahifar A.; Doschak M.R.; Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats. Pharm Res 2014,31(5),1146-1157","journal-title":"Pharm Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.biomaterials.2013.01.059","volume":"34","author":"Yewle J.N.","year":"2013","unstructured":"Yewle J.N.; Puleo D.A.; Bachas L.G.; Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity. Biomaterials 2013,34(12),3141-3149","journal-title":"Biomaterials"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","volume":"20","author":"Arns S.","year":"2012","unstructured":"Arns S.; Gibe R.; Moreau A.; Monzur Morshed M.; Young R.N.; Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis. Bioorg Med Chem 2012,20(6),2131-2140","journal-title":"Bioorg Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/ijms17030428","volume":"17","author":"Dang L.","year":"2016","unstructured":"Dang L.; Liu J.; Li F.; Targeted delivery systems for molecular therapy in skeletal disorders. Int J Mol Sci 2016,17(3),428","journal-title":"Int J Mol Sci"},{"key":"ref=53","first-page":"5671","volume":"10","author":"Wang H.","year":"2015","unstructured":"Wang H.; Liu J.; Tao S.; Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. Int J Nanomedicine 2015,10,5671-5685","journal-title":"Int J Nanomedicine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/ijms20092213","volume":"20","author":"Chen L.R.","year":"2019","unstructured":"Chen L.R.; Ko N.Y.; Chen K.H.; Medical treatment for osteoporosis: From molecular to clinical opinions. Int J Mol Sci 2019,20(9),2213","journal-title":"Int J Mol Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.22203\/eCM.v023a24","volume":"23","author":"Ansboro S.","year":"2012","unstructured":"Ansboro S.; Greiser U.; Barry F.; Murphy M.; Strategies for improved targeting of therapeutic cells: implications for tissue repair. Eur Cell Mater 2012,23,310-318","journal-title":"Eur Cell Mater"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jconrel.2011.10.001","volume":"161","author":"Luhmann T.","year":"2012","unstructured":"Luhmann T.; Germershaus O.; Groll J.; Meinel L.; Bone targeting for the treatment of osteoporosis. J Control Release 2012,161(2),198-213","journal-title":"J Control Release"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1759720X14523500","volume":"6","author":"Rochefort G.Y.","year":"2014","unstructured":"Rochefort G.Y.; The osteocyte as a therapeutic target in the treatment of osteoporosis. Ther Adv Musculoskelet Dis 2014,6(3),79-91","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1080\/00325481.2017.1362312","volume":"129","author":"Corrado A.","year":"2017","unstructured":"Corrado A.; Sanpaolo E.R.; Di Bello S.; Cantatore F.P.; Osteoblast as a target of anti-osteoporotic treatment. Postgrad Med 2017,129(8),858-865","journal-title":"Postgrad Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1517\/14728222.9.5.1063","volume":"9","author":"Rawadi G.","year":"2005","unstructured":"Rawadi G.; Roman-Roman S.; Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 2005,9(5),1063-1077","journal-title":"Expert Opin Ther Targets"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","volume":"57","author":"Wang D.","year":"2005","unstructured":"Wang D.; Miller S.C.; Kopeckov\u00e1 P.; Kope\u010dek J.; Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 2005,57(7),1049-1076","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12929-018-0439-z","volume":"25","author":"Wang H.H.","year":"2018","unstructured":"Wang H.H.; Hsu Y.H.; Chang M.S.; IL-20 bone diseases involvement and therapeutic target potential. J Biomed Sci 2018,25(1),38","journal-title":"J Biomed Sci"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_329","author":"Brommage R.","year":"2019","unstructured":"Brommage R.; New Targets and Emergent Therapies for Osteoporosis. Handb Exp Pharmacol 2019","journal-title":"Handb Exp Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s11914-016-0321-4","volume":"14","author":"Asafo-Adjei T.A.","year":"2016","unstructured":"Asafo-Adjei T.A.; Chen A.J.; Najarzadeh A.; Puleo D.A.; Advances in controlled drug delivery for treatment of osteoporosis. Curr Osteoporos Rep 2016,14(5),226-238","journal-title":"Curr Osteoporos Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1530\/EJE-11-0646","volume":"166","author":"Taipaleenm\u00e4ki H.","year":"2012","unstructured":"Taipaleenm\u00e4ki H.; Bjerre Hokland L.; Chen L.; Kauppinen S.; Kassem M.; Mechanisms in endocrinology: micro-RNAs: targets for enhancing osteoblast differentiation and bone formation. Eur J Endocrinol 2012,166(3),359-371","journal-title":"Eur J Endocrinol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbrc.2019.11.043","volume":"522","author":"Huang Y.","year":"2020","unstructured":"Huang Y.; Ren K.; Yao T.; MicroRNA-25-3p regulates osteoclasts through nuclear factor I X. Biochem Biophys Res Commun 2020,522(1),74-80","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","volume":"10","author":"Sun Y.","year":"2016","unstructured":"Sun Y.; Ye X.; Cai M.; Osteoblast-targeting-peptide modified nanoparticle for siRNA\/microRNA delivery. ACS Nano 2016,10(6),5759-5768","journal-title":"ACS Nano"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ijms20030565","volume":"20","author":"Qadir A.","year":"2019","unstructured":"Qadir A.; Gao Y.; Suryaji P.; Non-viral delivery system and targeted bone disease therapy. Int J Mol Sci 2019,20(3),565","journal-title":"Int J Mol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nm.3791","volume":"21","author":"Liang C.","year":"2015","unstructured":"Liang C.; Guo B.; Wu H.; Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 2015,21(3),288-294","journal-title":"Nat Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fcell.2018.00170","volume":"6","author":"Houschyar K.S.","year":"2019","unstructured":"Houschyar K.S.; Tapking C.; Borrelli M.R.; Wnt pathway in bone repair and regeneration. Front Cell Dev Biol 2019,6,170","journal-title":"Front Cell Dev Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1172\/JCI33612","volume":"118","author":"Khosla S.","year":"2008","unstructured":"Khosla S.; Westendorf J.J.; Oursler M.J.; Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008,118(2),421-428","journal-title":"J Clin Invest"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/09205063.2017.1399001","volume":"29","author":"Cho M.","year":"2018","unstructured":"Cho M.; Han S.; Kim H.; Kim K.S.; Hahn S.K.; Hyaluronate - parathyroid hormone peptide conjugate for transdermal treatment of osteoporosis. J Biomater Sci Polym Ed 2018,29(7-9),793-804","journal-title":"J Biomater Sci Polym Ed"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1021\/acsnano.9b00241","volume":"13","author":"Mora-Raimundo P.","year":"2019","unstructured":"Mora-Raimundo P.; Lozano D.; Manzano M.; Vallet-Reg\u00ed M.; Nanoparticles to Knockdown osteoporosis-related gene and promote osteogenic marker expression for osteoporosis treatment. ACS Nano 2019,13(5),5451-5464","journal-title":"ACS Nano"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1096\/fj.201902319RRR","volume":"34","author":"Yu A.X.","year":"2020","unstructured":"Yu A.X.; Xu M.L.; Yao P.; Corylin, a flavonoid derived from Psoralea Fructus, induces osteoblastic differentiation via estrogen and Wnt\/\u03b2-catenin signaling pathways. FASEB J 2020,34(3),4311-4328","journal-title":"FASEB J"},{"key":"ref=74","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104366","volume":"\u2022","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Jiang Y.; Luo Y.; Zeng Y.; Interference of miR-212 and miR-384 promotes osteogenic differentiation via targeting RUNX2 in osteoporosis. Exp Mol Pathol 2020,\u2022","journal-title":"Exp Mol Pathol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1590\/S0482-50042011000400008","volume":"51","author":"Khajuria D.K.","year":"2011","unstructured":"Khajuria D.K.; Razdan R.; Mahapatra D.R.; Drugs for the management of osteoporosis: a review. Rev Bras Reumatol 2011,51(4),365-371, 379-382","journal-title":"Rev Bras Reumatol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1021\/acs.jmedchem.6b00951","volume":"60","author":"Xie H.","year":"2017","unstructured":"Xie H.; Chen G.; Young R.N.; Design, synthesis, and pharmacokinetics of a bone-targeting dual-action prodrug for the treatment of osteoporosis. J Med Chem 2017,60(16),7012-7028","journal-title":"J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3389\/fmed.2017.00234","volume":"4","author":"Bi H.","year":"2017","unstructured":"Bi H.; Chen X.; Gao S.; Key triggers of osteoclast-related diseases and available strategies for targeted therapies: A review. Front Med (Lausanne) 2017,4,234","journal-title":"Front Med (Lausanne)"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/jfb3010079","volume":"3","author":"Pignatello R.","year":"2012","unstructured":"Pignatello R.; Sarpietro M.G.; Castelli F.; Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater 2012,3(1),79-99","journal-title":"J Funct Biomater"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/jbmr.3012","volume":"32","author":"Schem C.","year":"2017","unstructured":"Schem C.; Tower R.J.; Kneissl P.; Pharmacologically inactive bisphosphonates as an alternative strategy for targeting osteoclasts: in vivo assessment of 5\u2010fluorodeoxyuridine\u2010alendronate in a preclinical model of breast cancer bone metastases. J Bone Miner Res 2017,32(3),536-548","journal-title":"J Bone Miner Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.12688\/f1000research.17296.1","volume":"8","author":"Tanaka S.","year":"2019","unstructured":"Tanaka S.; RANKL is a therapeutic target of bone destruction in rheumatoid arthritis. F1000 Res 2019,8,8","journal-title":"F1000 Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"438","DOI":"10.6061\/clinics\/2014(06)12","volume":"69","author":"Nardone V.","year":"2014","unstructured":"Nardone V.; D\u2019Asta F.; Brandi M.L.; Pharmacological management of osteogenesis. Clinics (S\u00e3o Paulo) 2014,69(6),438-446","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/13543780902832661","volume":"18","author":"Br\u00f6mme D.","year":"2009","unstructured":"Br\u00f6mme D.; Lecaille F.; Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009,18(5),585-600","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=83","author":"Kim HY","year":"2019","unstructured":"Kim HY; Kim KS; Kim MJ; Kim HS; Lee KY; Kang KW;  Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of \u03baB Kinase and Inflammasome-Mediated Interleukin-1\u03b2 Secretion Oxidative med cell Longev 2019","journal-title":"Auranofin Inhibits RANKL-Induced Osteoclastogenesis by Suppressing Inhibitors of \u03baB Kinase and Inflammasome-Mediated Interleukin-1\u03b2 Secretion Oxidative med cell Longev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.7150\/thno.28391","volume":"8","author":"Duan X.","year":"2018","unstructured":"Duan X.; Yang S.; Zhang L.; Yang T.; V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis. Theranostics 2018,8(19),5379-5399","journal-title":"Theranostics"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/BOR.0b013e328356d212","volume":"24","author":"Kawai V.K.","year":"2012","unstructured":"Kawai V.K.; Stein C.M.; Perrien D.S.; Griffin M.R.; Effects of anti-tumor necrosis factor \u03b1 agents on bone. Curr Opin Rheumatol 2012,24(5),576-585","journal-title":"Curr Opin Rheumatol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msec.2017.03.235","volume":"78","author":"Babanejad N.","year":"2017","unstructured":"Babanejad N.; Farhadian A.; Omrani I.; Nabid M.R.; Design, characterization and in vitro evaluation of novel amphiphilic block sunflower oil-based polyol nanocarrier as a potential delivery system: Raloxifene-hydrochloride as a model. Mater Sci Eng C 2017,78,59-68","journal-title":"Mater Sci Eng C"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s11095-015-1827-7","volume":"33","author":"Ye Y.","year":"2016","unstructured":"Ye Y.; Zhang T.; Li W.; Glucose-based mesoporous carbon nanospheres as functional carriers for oral delivery of amphiphobic raloxifene: Insights into the bioavailability enhancement and lymphatic transport. Pharm Res 2016,33(3),792-803","journal-title":"Pharm Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12951-019-0447-5","volume":"17","author":"Sun X.","year":"2019","unstructured":"Sun X.; Wei J.; Lyu J.; Bone-targeting drug delivery system of biomineral-binding liposomes loaded with icariin enhances the treatment for osteoporosis. J Nanobiotechnology 2019,17(1),10","journal-title":"J Nanobiotechnology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3109\/10717544.2014.900153","volume":"22","author":"Saini D.","year":"2015","unstructured":"Saini D.; Fazil M.; Ali M.M.; Baboota S.; Ali J.; Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 2015,22(6),823-836","journal-title":"Drug Deliv"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejps.2014.10.015","volume":"66","author":"Khajuria D.K.","year":"2015","unstructured":"Khajuria D.K.; Razdan R.; Mahapatra D.R.; Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model. Eur J Pharm Sci 2015,66,173-183","journal-title":"Eur J Pharm Sci"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3109\/10717544.2014.1002947","volume":"23","author":"Fazil M.","year":"2016","unstructured":"Fazil M.; Hassan M.Q.; Baboota S.; Ali J.; Biodegradable intranasal nanoparticulate drug delivery system of risedronate sodium for osteoporosis. Drug Deliv 2016,23(7),2428-2438","journal-title":"Drug Deliv"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3892\/etm.2018.6263","volume":"16","author":"Cai Y.","year":"2018","unstructured":"Cai Y.; Gao T.; Fu S.; Sun P.; Development of zoledronic acid functionalized hydroxyapatite loaded polymeric nanoparticles for the treatment of osteoporosis. Exp Ther Med 2018,16(2),704-710","journal-title":"Exp Ther Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ijpharm.2019.04.069","volume":"564","author":"Elnaggar Y.S.R.","year":"2019","unstructured":"Elnaggar Y.S.R.; Omran S.; Hazzah H.A.; Abdallah O.Y.; Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm 2019,564,410-425","journal-title":"Int J Pharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.2147\/IJN.S139775","volume":"12","author":"Cai M.","year":"2017","unstructured":"Cai M.; Yang L.; Zhang S.; Liu J.; Sun Y.; Wang X.; A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy. Int J Nanomedicine 2017,12,7469-7482","journal-title":"Int J Nanomedicine"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"27336","DOI":"10.1038\/srep27336","volume":"6","author":"Lee D.","year":"2016","unstructured":"Lee D.; Heo D.N.; Kim H.J.; Inhibition of osteoclast differentiation and bone resorption by bisphosphonate-conjugated gold nanoparticles. Sci Rep 2016,6(1),27336","journal-title":"Sci Rep"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1021\/acs.jafc.8b06954","volume":"67","author":"Tan H.","year":"2019","unstructured":"Tan H.; Zhao C.; Zhu Q.; Ursolic Acid Isolated from the Leaves of Loquat (Eriobotrya japonica) Inhibited Osteoclast Differentiation through Targeting Exportin 5. J Agric Food Chem 2019,67(12),3333-3340","journal-title":"J Agric Food Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1242\/dmm.019091","volume":"9","author":"Yu T.","year":"2016","unstructured":"Yu T.; Witten P.E.; Huysseune A.; Buettner A.; To T.T.; Winkler C.; Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model. Dis Model Mech 2016,9(2),155-163","journal-title":"Dis Model Mech"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.1021\/acs.jmedchem.9b00932","volume":"62","author":"Abdelsamie A.S.","year":"2019","unstructured":"Abdelsamie A.S.; Salah M.; Siebenb\u00fcrger L.; Design, Synthesis, and Biological Characterization of Orally Active 17\u03b2-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. J Med Chem 2019,62(15),7289-7301","journal-title":"J Med Chem"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/iub.2131","volume":"71","author":"Mao Z.","year":"2019","unstructured":"Mao Z.; Zhu Y.; Hao W.; Chu C.; Su H.; MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. IUBMB Life 2019,71(12),1916-1928","journal-title":"IUBMB Life"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2019.04.042","volume":"304","author":"Liu Y.","year":"2019","unstructured":"Liu Y.; Yu P.; Peng X.; Hexapeptide-conjugated calcitonin for targeted therapy of osteoporosis. J Control Release 2019,304,39-50","journal-title":"J Control Release"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.mattod.2015.12.003","volume":"19","author":"Wang Q","year":"2016","unstructured":"Wang Q; Yan J; Yang J; Li B; Nanomaterials promise better bone repair. Mater Today 2016,19(8),451-463","journal-title":"Mater Today"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184451\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T14:20:33Z","timestamp":1629901233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184451\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":101,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,12,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200731173522","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}